This Week in Cardiology — Aug 3, 2026

Welcome to This Week in Cardiology. This week we're covering nine notable papers spanning interventional and surgical revascularisation, cardiomyopathy imaging and pharmacotherapy, and the harder questions of anticoagulation, mechanical support, and personalised prescribing. Let's dive in.

We start with revascularisation, where The Lancet published the MIST trial, the first randomised comparison of multivessel minimally invasive coronary bypass through a small thoracotomy versus conventional median sternotomy [1]. Across seven centres in Canada, India, China, Germany, the United States, and Japan, 170 patients with multivessel disease were randomised, and the primary endpoint was patient-reported physical recovery at one month on the Short Form 36 Physical Component Summary. The minimally invasive group scored meaningfully higher — a mean difference of just under three points, which was statistically significant but modest in absolute terms. What is arguably more notable is the safety signal: through twelve months there were no deaths and no strokes in either arm, and a single major adverse cardiac or cerebrovascular event overall. Enrolment took more than six years for 176 patients, which tells you something important about generalisability — this was highly selected patients operated on by experienced teams, with no reoperations and no concomitant procedures. So the honest reading is proof of concept: in the right hands and the right patient, thoracotomy bypass buys a somewhat faster functional recovery without an evident safety penalty, but this is not yet a mandate to change referral patterns. Staying with the catheter lab, the Journal of the American Heart Association reported a Swedish registry analysis from SCAAR looking at something rarely discussed: how long you should inflate a drug-coated balloon [4]. Among more than eleven thousand patients, those inflated for at least thirty seconds had roughly half the rate of target segment revascularisation at one year compared with shorter inflations, and about a third the rate of target vessel myocardial infarction, with no difference in mortality. Only 412 patients were in the short-inflation group and the analysis is observational, so residual confounding by lesion complexity and operator behaviour is real — the short-inflation group had more proximal lesions. Still, the direction is biologically plausible, since drug transfer is time-dependent, and the practical message is cheap and easy: give the balloon thirty seconds.

Turning to cardiomyopathy, Circulation published a large international study that should simplify a common imaging dilemma [2]. Among 1,160 patients with dilated cardiomyopathy who had cardiac magnetic resonance imaging, and genetic testing in 86 percent, left ventricular hypertrabeculation — what we used to call noncompaction — was present in about thirty percent. Over five years of follow-up, embolic events occurred in only just over three percent of the whole cohort, and hypertrabeculation was not associated with embolic risk, including in patients in sinus rhythm with an ejection fraction at or below forty percent. Nor was it associated with ventricular arrhythmias or advanced heart failure. What did predict events was familiar: atrial fibrillation and reduced ejection fraction for embolism, and genotype, ejection fraction, and late gadolinium enhancement for adverse outcomes. Prevalence varied strikingly by genotype, from nearly sixty percent with motor sarcomeric variants down to five to seven percent in nuclear envelope and cytoskeletal genes. The clinical implication is direct: hypertrabeculation on cardiac magnetic resonance in dilated cardiomyopathy should not by itself trigger prophylactic anticoagulation or altered management. On the hypertrophic side, the European Journal of Heart Failure reported 48-week patient-reported outcomes from FOREST-HCM, the open-label extension for aficamten in obstructive hypertrophic cardiomyopathy [3]. In 172 participants, the Kansas City Cardiomyopathy Questionnaire overall summary score improved by nearly nineteen points, with the largest gains in the quality-of-life domain at almost twenty-six points, alongside significant improvements in Seattle Angina Questionnaire and EuroQol scores. Improvements appeared by week twelve and were sustained through week 48, and correlated with clinical markers of disease severity. This is open-label and uncontrolled, so expectation effects cannot be excluded, but the magnitude is well beyond typical clinically important thresholds and it argues that the symptomatic benefit seen in SEQUOIA-HCM does not fade over a year.

Our third theme groups papers asking when to withhold, when to escalate, and when to individualise. From the Journal of the American Heart Association, the STOP-OAC study followed 1,655 Japanese patients with a CHADS2 score of two or more after first-time atrial fibrillation ablation, using a landmark analysis at 240 days [5]. Beyond that point, ischaemic stroke rates were essentially identical whether or not anticoagulation had been stopped — roughly four to five events per thousand patient-years in each group — while major or clinically relevant bleeding was about four times lower off anticoagulation. The crucial caveat is that this was not randomised: the patients who stopped had less non-paroxysmal atrial fibrillation and far less prior stroke, seven percent versus twenty-three percent. So this supports the practice of selective discontinuation in low-burden, low-stroke-history patients rather than blanket withdrawal by CHADS2 score alone. Also in the same journal, a nationwide Japanese analysis of nearly nineteen thousand patients with cardiogenic shock on venoarterial extracorporeal membrane oxygenation compared left ventricular unloading with Impella versus intra-aortic balloon pump [6]. In-hospital mortality was fifty-seven percent with Impella versus sixty-seven percent with balloon pump, and after propensity weighting Impella was associated with about a fourteen percent relative reduction in the odds of death, with the clearest signals in heart failure and arrhythmia aetiologies. That came with roughly double the length of stay and double the cost. Only nine percent of the cohort received Impella, and unmeasured selection is an obvious limitation, so this is hypothesis-generating pending randomised data. A third paper in that journal delivered a negative result worth knowing: in ILLUMINATE-CS, among 242 patients with cardiac sarcoidosis and an ejection fraction below fifty percent, use of conventional heart failure medications at diagnosis was not significantly associated with the composite of death, heart failure hospitalisation, or fatal ventricular arrhythmia, in either unadjusted or overlap-weighted analyses [7]. The sample is small and confidence intervals wide, so this is not evidence of no effect — but it does argue against assuming that guideline-directed therapy alone addresses the inflammatory driver in this phenotype. Rounding out the week, the European Heart Journal published a pharmacogenomic analysis of antihypertensive side effects in over 400,000 genotyped medication users across FinnGen, the UK Biobank, and the Estonian Biobank [8]. Fourteen loci predicted switching away from ACE inhibitors and dihydropyridine calcium channel blockers, with convergence on the neurotensin–NTSR1 pathway — a Finnish-enriched protective NTSR1 variant more than halved the odds of switching and cut ACE-inhibitor cough risk by about sixty percent — and a calcium channel blocker locus in near-complete linkage with the functional CYP3A4*22 allele. A polygenic score identified people with roughly double the cough risk. Not yet actionable at the bedside, but it extends the bradykinin story and points toward genotype-guided antihypertensive selection. Alongside that, a European Heart Journal review argued that mineralocorticoid receptor overactivation is a unifying mechanism in heart failure with preserved ejection fraction, linking age, female sex, obesity, diabetes, and chronic kidney disease through renin-independent aldosterone excess and ligand-independent receptor activation, and noting that the non-steroidal antagonist finerenone significantly reduced worsening heart failure events and cardiovascular death, with possibly greater benefit at higher adiposity [9].

If you only have time for one paper this week, make it the Circulation study on hypertrabeculation in dilated cardiomyopathy [2]. It resolves a question that comes up in clinic every week and should stop unnecessary anticoagulation and unnecessary alarm after an incidental cardiac magnetic resonance finding.

Here are the key takeaways from this week in cardiology. Minimally invasive multivessel bypass improved one-month physical recovery versus sternotomy with no safety penalty at a year, but in highly selected patients and expert hands. Left ventricular hypertrabeculation in dilated cardiomyopathy does not predict embolic events, arrhythmia, or advanced heart failure, and should not drive prophylactic anticoagulation — genotype, ejection fraction, and late gadolinium enhancement do the prognostic work. Aficamten's symptomatic benefit in obstructive hypertrophic cardiomyopathy is sustained through 48 weeks in open-label follow-up. Inflate your drug-coated balloons for at least thirty seconds. Selective anticoagulation discontinuation after ablation in carefully chosen patients with a CHADS2 of two or more appears safe and reduces bleeding, but that selection matters more than the score. Impella unloading during extracorporeal support was associated with lower in-hospital mortality than a balloon pump at substantially higher cost, and conventional heart failure drugs showed no significant outcome benefit in cardiac sarcoidosis.

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.